Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Long-Term Debt by Year
Long-Term Debt — Current maturities due within 12 months ($M) ($M)
Pfizer Long-Term Debt: $3,000M in FY2025, down 20.0% from a year earlier.
Latest, FY2025
3,000
Period ended Dec 31, 2025
Change on a year earlier
-20.0%
3,750 in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Financial Instruments Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Long-Term Debt — Current maturities due within 12 months ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,000 | -20.0% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 3,750 | +66.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 2,250 | -11.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2022 | Dec 31, 2022 | 2,550 | +55.9% | Form 10-K (filed 2024-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 1,636 | -18.4% | Form 10-K (filed 2023-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 2,004 | +37.4% | Form 10-K (filed 2022-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 1,458 | -69.5% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 4,781 | +35.4% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 3,532 | -15.9% | Form 10-K (filed 2019-02-28) ↗ |
| FY2016 | Dec 31, 2016 | 4,201 | – | Form 10-K (filed 2018-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Long-Term Debt ($M), annual FY2016–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/debt-cur-mat
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.